<DOC>
	<DOCNO>NCT02193867</DOCNO>
	<brief_summary>This open-label , repeat-dose , study sebelipase alfa infant rapidly progressive LAL Deficiency . Eligible subject receive once-weekly infusion sebelipase alfa 3 year .</brief_summary>
	<brief_title>Clinical Trial Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency</brief_title>
	<detailed_description>Lysosomal Acid Lipase ( LAL ) Deficiency rare autosomal recessive lipid storage disorder cause marked decrease almost complete absence LAL enzyme , lead accumulation lipid , predominately cholesteryl ester triglyceride , various tissue cell type . In liver , accumulation lipid lead hepatomegaly , liver dysfunction , hepatic failure . In small intestine , lipid-laden macrophage accumulation lamina propria lead profound malabsorption . LAL Deficiency present infancy extremely rare form LAL Deficiency . It characterize profound malabsorption , growth failure , hepatic failure , usually fatal first 6 month life . There currently safe effective therapy treatment LAL Deficiency .</detailed_description>
	<mesh_term>Wolman Disease</mesh_term>
	<criteria>1 . Subject 's parent legal guardian ( applicable ) consent participation study . 2 . Confirmation LAL Deficiency diagnosis determine Sponsor approve central laboratory . 3 . Substantial clinical concern , opinion Investigator Sponsor , rapid disease progression require urgent medical intervention include , restrict , follow : Marked abdominal distension hepatomegaly Failure thrive Disturbance coagulation Severe anemia Sibling rapidly progressive course LAL Deficiency 1 . Clinically important concurrent disease 2 . Subject &gt; 8 month age time first dosing . 3 . Subject receive investigational medicinal product sebelipase alfa within 14 day prior first dose sebelipase alfa study . 4 . Myeloablative preparation , systemic pretransplant conditioning , hematopoietic stem cell liver transplantation . 5 . Previous hematopoietic stem cell liver transplant . 6 . Known hypersensitivity egg .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>8 Months</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>LIPA</keyword>
	<keyword>Wolman Disease</keyword>
	<keyword>Wolman Phenotype</keyword>
	<keyword>Acid Lipase Deficiency</keyword>
	<keyword>Acid Cholesteryl Hydrolase</keyword>
	<keyword>Acid Lipase Disease Deficiency , type 2</keyword>
	<keyword>Cholesteryl Ester Storage Disease ( CESD )</keyword>
	<keyword>Cholesteryl Ester Hydrolase Deficiency</keyword>
	<keyword>Early Onset Lysosomal Acid Lipase Deficiency ( Wolman Disease )</keyword>
	<keyword>LAL Deficiency</keyword>
	<keyword>Late Onset Lysosomal Acid Lipase Deficiency ( CESD )</keyword>
	<keyword>Wolman Disease ( early onset LAL Deficiency )</keyword>
	<keyword>Related Disorders :</keyword>
	<keyword>Non-alcoholic Fatty Liver Disease ( NAFLD )</keyword>
	<keyword>Non-alcoholic Steatohepatitis ( NASH )</keyword>
	<keyword>Alcoholic Liver Disease</keyword>
	<keyword>Cryptogenic Cirrhosis</keyword>
	<keyword>Niemann-Pick Disease ( NPD ) Type C</keyword>
	<keyword>Chanarin Dorfman Syndrome</keyword>
</DOC>